Overview

CVRx is a publicly-listed bioelectronic medicine company (NASDAQ: CVRX) developing Barostim, the only FDA-approved baroreflex neuromodulation therapy for heart failure. The company was founded in 2001 and is headquartered at 9201 West Broadway Avenue, Suite 650, Minneapolis, Minnesota.

The Barostim device

Barostim is an implantable bioelectronic system that delivers electrical pulses to baroreceptors in the carotid artery wall, modulating the autonomic nervous system to reduce the workload on a failing heart rather than stimulating the heart muscle directly. The device sits in the chest like a pacemaker with a thin lead running to a nerve cluster in the carotid artery. Barostim received FDA approval in August 2019.

2026 commercial milestones

CVRx logged four significant Barostim reimbursement and clinical milestones in 2026: (1) Category I CPT codes for the Barostim procedure took effect on 1 January 2026, replacing the Category III codes the therapy had previously used; (2) the Centers for Medicare & Medicaid Services approved Category B IDE coverage in January 2026 for patients enrolled in CVRx’s BENEFIT-HF expanded-population pivotal trial; (3) CVRx enrolled the first patient in BENEFIT-HF on 4 May 2026 at North Central Heart in Sioux Falls, South Dakota; and (4) Humana issued the first Medicare Advantage coverage policy for Barostim on 14 May 2026, with the policy effective 1 May 2026.

The Category I CPT switch is already moving CVRx’s 30-day Medicare Advantage prior-authorization approval rates, from 31% in 2024 to 44% in 2025 to 50% in the first two months of 2026.

BENEFIT-HF pivotal trial

BENEFIT-HF is one of the largest cardiac device trials in heart failure history. The randomised controlled trial is enrolling 2,500 patients at approximately 150 hospitals in the United States and Germany. The primary endpoint is a composite of all-cause mortality and heart-failure hospitalisations, measured through 2032. The trial expands eligibility to patients with left ventricular ejection fraction below 50%, substantially broader than Barostim’s current label. If BENEFIT-HF reads out positively, CVRx expects the indicated patient population to expand by approximately three times.

Strategic position

CVRx is the most commercially advanced baroreflex neuromodulation company and a leading example of the broader bioelectronic-medicine commercial inflection that has hardened across 2026. The company’s reimbursement scaffolding (Category I CPT + CMS Category B IDE + Humana Medicare Advantage coverage) compounds ahead of the BENEFIT-HF pivotal readout, with the clinical and commercial layers building in parallel rather than sequentially.